Tivozanib hydrochloride (682745-41-1)

Home » APIs » Tivozanib hydrochloride

What is Tivozanib hydrochloride?

Tivozanib Hydrochloride is the hydrochloride salt of tivozanib. It is an oral VEGF receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Fotivda is one of the many brand names that are used to refer to tivozanib hydrochloride.

Tivozanib was granted permission for use in the treatment of medical conditions in the European Union in August 2017, and in the United States in March 2021.

Mechanism of action

The drug tivozanib belongs to a group of medicines known as kinase inhibitors. It works by blocking the action of vascular endothelial growth factor (VEGF), the abnormal protein that signals cancer cells to multiply, thus suppresses angiogenesis. This assists in preventing or slowing the spread of cancer cells. Its purpose is to block the activity of all three VEGF receptors.

Uses

Tivozanib is prescribed to people who have undergone two or more previous systemic treatments for their advanced renal cell carcinoma (RCC, cancer that begins in the kidneys) and have experienced a relapse or a lack of response to those treatments.

Side effects

Common side effects associated with the use of Tivozanib hydrochloride include:

• Nausea, vomiting, diarrhea, loss of appetite
• Feeling weak or tired
• Dysphonia (hoarse voice)
• Mouth sores
• Hypertension

Some of the serious side effects include:

• Unusual bruising or bleeding
• Bloody or black and tarry stools
• Blood in urine
• Vomiting or coughing up blood
• Bleeding from gums
• Seizures, headaches, vision changes, or confusion
• Redness, swelling, and pain on hands and/or feet
• Confusion, headache, dizziness, chest pain, or shortness of breath
• Numbness or weakness on one side of body; pain in arms, back, neck or jaw; difficulty talking; sudden severe headache; vision changes

FAQs

Q. Is it safe to consume Tivozanib during pregnancy?

Tivozanib should not be taken during pregnancy because it could potentially cause teratogenic effects.

Q. Is Tivozanib FDA approved?

Tivozanib, a kinase inhibitor, was granted approval by the Food and Drug Administration (FDA) on March 10, 2021 for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC) in adult patients who had previously undergone two or more systemic treatments.